CIRM Funded Clinical Trials

# Phase 2b Clinical Study of Safety and Efficacy of Intravitreal Injection of Retinal Progenitor Cells (jCell) for Treatment of Retinitis Pigmentosa

| | |
|---|---|
| **Disease Area:** | Retinitis Pigmentosa |
| **Investigator:** | Henry Klassen |
| **Institution:** | jCyte, Inc |
| **CIRM Grant:** | CLIN2-09698 |
| **Award Value:** | $8,295,750 |
| **Trial Sponsor:** | jCyte, Inc |
| **Trial Stage:** | Phase 2 |
| **Trial Status:** | Recruiting |
| **Targeted Enrollment:** | 85 |
| **ClinicalTrials.gov ID:** | NCT03073733 |

Henry Klassen

**Details:**
Retinitis pigmentosa (RP) is a severe form of blindness that runs in families with an incidence of 1:4000. A team at UC Irvine, is using cells called retinal progenitor cells to repair the damage caused by this vision destroying disease. The cells are injected into the back of the eye and it's hoped they will help preserve the photoreceptors attacked by RP as well as generate new photo receptors to replace those destroyed by the disease. This is a follow-on study based on an earlier CIRM-funded Phase 1/2a clinical trial out of UC Irvine. This Phase 2 trial will continue to assess safety and establish efficacy of this treatment.

**Design:**
Single dose. Randomized 1:1. Placebo-controlled with crossover option after 12 month follow up of treated group.

**Goal:**
Safety and efficacy - improvement in visual function at 12 months.

**Updates:**
This study is currently recruiting participants. RMAT designation was awarded in May 2017.

**News Releases:**
jCyte Receives Regenerative Medicine Advanced Therapy Designation

Contact Trial Sponsor

**Source URL:** https://www.cirm.ca.gov/clinical-trial/phase-2b-clinical-study-safety-and-efficacy-intravitreal-injection-retinal-progenitor